文献速递系统性红斑狼疮

系统性红斑狼疮患者SARS-CoV-2感染的临床与特殊免疫表现

Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

无症状感染者与SLE主要器官受累(尤其肾脏)及慢性糖皮质激素治疗相关,感染后仅3例(5.9%)出现SLE flare,未发现SARS-CoV-2感染风险增加。

要点

  • SLE患者SARS-CoV-2感染率为6.14%,无症状感染占17.6%。
  • SLE主要器官受累(尤其肾脏)与无症状感染相关(P=0.02)。
  • 慢性糖皮质激素治疗与无症状感染相关(P=0.018),感染后SLE flare仅5.9%。

核心结论

  • SARS-CoV-2感染在少数SLE患者中引起自身免疫 flare。
  • 数据似乎证实SLE患者SARS-CoV-2感染风险并未增加。
  • 无症状SARS-CoV-2感染者多为具有SLE主要器官受累的患者,可能与高剂量糖皮质激素和免疫抑制剂治疗有关。

研究设计与样本

  • 多中心研究,监测2020年2月至2021年3月意大利4个中心的SLE患者。
  • 记录感染前后的疾病特征、治疗、疾病活动度及SARS-CoV-2相关症状。

主要发现

  • 42例有症状患者中5例(9.8%)发展为间质性肺炎,未发现明确危险因素。
  • SLE主要器官受累(尤其肾脏受累)与无症状SARS-CoV-2感染相关(P=0.02)。
  • 慢性糖皮质激素治疗与无症状感染相关(P=0.018)。
  • 感染后出现3例(5.9%)SLE flare,其中1例为MPO-ANCA阳性寡免疫复合物新月体坏死性肾小球肾炎伴肉芽肿性肺炎。

临床怎么用

  • SLE患者感染SARS-CoV-2后应警惕少数flare可能,尤其注意肾脏及ANCA相关表现。
  • 对具有主要器官受累且使用慢性糖皮质激素的SLE患者,需关注无症状SARS-CoV-2感染可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with SLE remains unclear and data on clinical manifestations after infection are lacking. The aim of this multicentre study is to describe the effect of SARS-CoV-2 in SLE patients. METHODS: SLE patients referring to four Italian centres were monitored between February 2020 and March 2021. All patients with SARS-CoV-2 infection were included. Disease characteristics, treatment, disease activity and SARS-CoV-2-related symptoms were recorded before and after the infection. RESULTS: Fifty-one (6.14%) SLE patients were included among 830 who were regularly followed up. Nine (17.6%) had an asymptomatic infection and 5 (9.8%) out of 42 (82.6%) symptomatic patients developed interstitial pneumonia (no identified risk factor). The presence of SLE major organ involvement (particularly renal involvement) was associated with asymptomatic SARS-CoV-2 infection (P = 0.02). Chronic corticosteroid therapy was found to be associated with asymptomatic infection (P = 0.018). Three SLE flares (5.9%) were developed after SARS-CoV-2 infection: one of them was characterized by MPO-ANCA-positive pauci-immune crescentic necrotizing glomerulonephritis and granulomatous pneumonia. CONCLUSIONS: SARS-CoV-2 infection determined autoimmune flares in a small number of patients. Our data seem to confirm that there was not an increased risk of SARS-CoV-2 in SLE. Patients with asymptomatic SARS-CoV-2 infections were those having major SLE organ involvement. This may be explained by the high doses of corticosteroids and immunosuppressive agents used for SLE treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Schioppo T, Argolini LM, Sciascia S, et al. Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology (Oxford). 2022. PMID: 34352079. doi:10.1093/rheumatology/keab611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。